Home › Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
 

Keywords :   


Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody

2015-09-02 08:04:11| drugdiscoveryonline News Articles

Incyte Corporation recently announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody

Tags: global agreement license medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »